Wound treatments and compositions

Patent metadata

Field	Value
Publication number	US-12521391-B2
Application number	US-202418967341-A
Country	US
Kind code	B2
Filing date	Dec 3, 2024
Priority date	Apr 11, 2019
Publication date	Jan 13, 2026
Grant date	Jan 13, 2026

Abstract

A method of treating a wound may include topically administering a statin composition including a statin selected from atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or combination thereof. The statin composition may be administered in an ointment, powder, or liquid format. The method may also include topically administering one or more antimicrobial drugs and/or naltrexone.

First claim

What is claimed is:

1 . A method of formulating a topical wound treatment composition for administration to a skin wound, the method comprising:
mixing dry powder comprising (a) 5 mg to 200 mg of one or more statins selected from atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin or simvastatin, (b) lactose monohydrate, (c) magnesium stearate, and (d) microcrystalline cellulose with petrolatum, a water-washable-ointment, or a cream type vehicle.

2 . The method of formulating a topical wound treatment composition for administration to a skin wound of claim 1 , further comprising mixing between 1 mg and 50 mg naltrexone with the petrolatum, a water-washable-ointment, or a cream type vehicle.

3 . The method of formulating a topical wound treatment composition for administration to a skin wound of claim 1 , further comprising mixing between 1 mg and 50 mg naltrexone and/or at least one of an antibiotic drug and an antifungal drug with the petrolatum, a water-washable-ointment, or a cream type vehicle.

4 . The method of formulating a topical wound treatment composition for administration to a skin wound of claim 3 , wherein the topical wound treatment composition comprises the water-washable-ointment, and wherein the water-washable-ointment comprises PEG-8, PEG-75, meadowsweet extract, zinc acetate, and propylene glycol.

5 . The method of formulating a topical wound treatment composition for administration to a skin wound of claim 1 , further comprising mixing butylated hydroxyanisole with the petrolatum, a water-washable-ointment, or a cream type vehicle.

6 . The method of formulating a topical wound treatment composition for administration to a skin wound of claim 1 , wherein the dry powder further comprise between 1 mg and 50 mg naltrexone and/or at least one of an antibiotic drug or an antifungal drug.

7 . A method of treating a wound comprising:
administering to tissue of a skin wound a topical wound treatment composition comprising (a) 5 mg to 200 mg of one or more statins selected from atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin or simvastatin, (b) xylitol, (c) poloxamers, (d) lactose monohydrate, (e) magnesium stearate, and (f) microcrystalline cellulose with petrolatum, a water-washable-ointment, or a cream type vehicle.

8 . The method of treating a wound of claim 7 , wherein the topical wound treatment composition further comprises between 1 mg and 50 mg naltrexone.

9 . The method of treating a wound of claim 7 , wherein the topical wound treatment composition further comprises between 1 mg and 50 mg naltrexone and/or at least one of an antibiotic drug and an antifungal drug.

10 . The method of treating a wound of claim 9 , wherein the topical wound treatment composition comprises the water-washable-ointment, and wherein the water-washable-ointment comprises PEG-8, PEG-75, meadowsweet extract, zinc acetate, and propylene glycol.

11 . The method of treating a wound of claim 7 , wherein the topical wound treatment composition further comprises butylated hydroxyanisole.

12 . The method of treating a wound of claim 7 , wherein the topical wound treatment composition further comprises at least one of an antibiotic drug or an antifungal drug.

13 . A method of treating a wound comprising:
administering to tissue of a skin wound a topical wound treatment composition comprising (a) 5 mg to 200 mg of one or more statins selected from atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin or simvastatin, (b) lactose monohydrate, (c) magnesium stearate, and (d) microcrystalline cellulose with petrolatum, a water-washable-ointment, or a cream type vehicle.

14 . The method of treating a wound of claim 13 , wherein the topical wound treatment composition further comprises between 1 mg and 50 mg naltrexone.

15 . The method of treating a wound of claim 13 , wherein the topical wound treatment composition further comprises between 1 mg and 50 mg naltrexone and/or at least one of an antibiotic drug and an antifungal drug.

16 . The method of treating a wound of claim 15 , wherein the topical wound treatment composition comprises the water-washable-ointment, and wherein the water-washable-ointment comprises PEG-8, PEG-75, meadowsweet extract, zinc acetate, and propylene glycol.

17 . The method of treating a wound of claim 13 , wherein the topical wound treatment composition further comprises butylated hydroxyanisole.

18 . The method of treating a wound of claim 17 , wherein the topical wound treatment composition further comprises between 1 mg and 50 mg naltrexone and/or at least one of an antibiotic drug or an antifungal drug.

Assignees

• Cmpd Licensing Llc

Inventors

• Ray Ii Jay Richard

Classifications

• A61K31/405

  Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin · CPC title

• A61K31/485

  Morphinan derivatives, e.g. morphine, codeine · CPC title

• A61K31/47

  Quinolines; Isoquinolines · CPC title

• A61K31/366

  having six-membered rings, e.g. delta-lactones · CPC title

• A61K9/06

  Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)} · CPC title